{
    "organizations": [],
    "uuid": "1b8da48cee114a2b6ad40abde05fe3409e624297",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-idorsia-starts-phase-3-registratio/brief-idorsia-starts-phase-3-registration-study-to-assess-lucerastat-as-potential-new-treatment-option-for-patients-with-fabry-disease-idUSASO0004UY",
    "ord_in_thread": 0,
    "title": "BRIEF-Idorsia Starts Phase 3 Registration Study To Assess Lucerastat As Potential New Treatment Option For Patients With Fabry Disease",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 16 (Reuters) - IDORSIA LTD:\n* IDORSIA INITIATES MODIFY, A PHASE 3 REGISTRATION STUDY TO ASSESS LUCERASTAT AS A POTENTIAL NEW TREATMENT OPTION FOR PATIENTS WITH FABRY DISEASE Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-05-16T13:05:00.000+03:00",
    "crawled": "2018-05-17T14:29:14.023+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "idorsia",
        "ltd",
        "idorsia",
        "initiate",
        "modify",
        "phase",
        "registration",
        "study",
        "assess",
        "lucerastat",
        "potential",
        "new",
        "treatment",
        "option",
        "patient",
        "fabry",
        "disease",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}